SCHEMBL19676830

SCHEMBL19676830

O=NC(=O)CNC(=O)c1ncc(-c2cccc(F)c2)cc1N=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 16/20 0.58
VEGFA P15692 4/20 0.44
FLT1 P17948 4/20 0.44
EGLN3 Q9H6Z9 4/20 0.44
TET3 O43151 1/20 0.44
BBOX1 O75936 1/20 0.44
ASPH Q12797 1/20 0.44
TET2 Q6N021 1/20 0.44
KDM8 Q8N371 1/20 0.44
OGFOD1 Q8N543 1/20 0.44
TET1 Q8NFU7 1/20 0.44
HIF1AN Q9NWT6 1/20 0.44
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
THPO P40225 1/20 0.41
LMNA P02545 1/20 0.40
PMP22 Q01453 1/20 0.40
MAP4K4 O95819 1/20 0.39
FTO Q9C0B1 1/20 0.39
GRIN2B Q13224 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21444651 0.88 EGLN1 (0.59) EGLN1VEGFAFLT1EGLN3TET3
SCHEMBL19676954 0.87 EGLN1 (0.77) EGLN1VEGFAFLT1EGLN3TET3
SCHEMBL20171240 0.77 EGLN1 (0.55) EGLN1VEGFAFLT1EGLN3GRIN2B
SCHEMBL25777345 0.77 EGLN1 (0.73) EGLN1VEGFAFLT1EGLN3TET3
SCHEMBL24405090 0.75 EGLN1 (0.58) EGLN1VEGFAFLT1EGLN3TET3
SCHEMBL3484399 0.74 EGLN1 (1.00) EGLN1VEGFAFLT1EGLN3TET3
SCHEMBL30145054 0.74 EGLN1 (1.00) EGLN1VEGFAFLT1EGLN3TET3
SCHEMBL3484933 0.74 EGLN1 (0.78) EGLN1VEGFAFLT1EGLN3TET3
SCHEMBL14225535 0.73 EGLN1 (0.80) EGLN1VEGFAFLT1EGLN3TET3
Ammonia Solution, Strong SCHEMBL14165936 0.73 EGLN1 (0.98) EGLN1VEGFAFLT1EGLN3TET3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3251671-A1 COMPOSITIONS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER Akebia Therapeutics Inc. (US) 2017-12-06 EP disclosed